There were 1,379 press releases posted in the last 24 hours and 401,270 in the last 365 days.

Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Nov. 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harvard Bioscience, Inc. (NASDAQ:HBIO), TTM Technologies, Inc. (NASDAQ:TTMI), BSQUARE Corporation (NASDAQ:BSQR), United Therapeutics Corporation (NASDAQ:UTHR), KCAP Financial, Inc. (NASDAQ:KCAP), and Gladstone Capital Corporation (NASDAQ:GLAD), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

HBIO DOWNLOAD: http://Fundamental-Markets.com/register/?so=HBIO
TTMI DOWNLOAD: http://Fundamental-Markets.com/register/?so=TTMI
BSQR DOWNLOAD: http://Fundamental-Markets.com/register/?so=BSQR
UTHR DOWNLOAD: http://Fundamental-Markets.com/register/?so=UTHR
KCAP DOWNLOAD: http://Fundamental-Markets.com/register/?so=KCAP
GLAD DOWNLOAD: http://Fundamental-Markets.com/register/?so=GLAD

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Harvard Bioscience, Inc. (NASDAQ:HBIO), TTM Technologies, Inc. (NASDAQ:TTMI), BSQUARE Corporation (NASDAQ:BSQR), United Therapeutics Corporation (NASDAQ:UTHR), KCAP Financial, Inc. (NASDAQ:KCAP), and Gladstone Capital Corporation (NASDAQ:GLAD) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 21st, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

HARVARD BIOSCIENCE, INC. (HBIO) REPORT OVERVIEW

Harvard Bioscience's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Harvard Bioscience reported revenue of $28.64MM vs $18.72MM (up 52.99%) and analysts estimated basic earnings per share -$0.01 vs -$0.01. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Harvard Bioscience reported revenue of $101.88MM vs $104.52MM (down 2.52%) and analysts estimated basic earnings per share -$0.02 vs -$0.13. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal year is $0.20 and is expected to report on March 7th, 2019.

To read the full Harvard Bioscience, Inc. (HBIO) report, download it here: http://Fundamental-Markets.com/register/?so=HBIO

-----------------------------------------

TTM TECHNOLOGIES, INC. (TTMI) REPORT OVERVIEW

TTM Technologies' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, TTM Technologies reported revenue of $755.84MM vs $666.81MM (up 13.35%) and analysts estimated basic earnings per share $0.26 vs $0.21 (up 23.81%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, TTM Technologies reported revenue of $2,658.59MM vs $2,533.36MM (up 4.94%) and analysts estimated basic earnings per share $1.22 vs $0.35 (up 248.57%). Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.40. The estimated EPS forecast for the next fiscal year is $0.77 and is expected to report on February 6th, 2019.

To read the full TTM Technologies, Inc. (TTMI) report, download it here: http://Fundamental-Markets.com/register/?so=TTMI

-----------------------------------------

BSQUARE CORPORATION (BSQR) REPORT OVERVIEW

BSQUARE's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, BSQUARE reported revenue of $16.69MM vs $19.65MM (down 15.06%) and analysts estimated basic earnings per share -$0.16 vs -$0.20. For the twelve months ended December 31st, 2017 vs December 31st, 2016, BSQUARE reported revenue of $80.81MM vs $97.44MM (down 17.07%) and analysts estimated basic earnings per share -$0.72 vs -$0.09. Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full BSQUARE Corporation (BSQR) report, download it here: http://Fundamental-Markets.com/register/?so=BSQR

-----------------------------------------

UNITED THERAPEUTICS CORPORATION (UTHR) REPORT OVERVIEW

United Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, United Therapeutics reported revenue of $412.70MM vs $445.50MM (down 7.36%) and basic earnings per share $2.44 vs $6.37 (down 61.70%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, United Therapeutics reported revenue of $1,725.30MM vs $1,598.80MM (up 7.91%) and analysts estimated basic earnings per share $9.50 vs $16.29 (down 41.68%). Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $2.06. The estimated EPS forecast for the next fiscal year is $8.85 and is expected to report on February 20th, 2019.

To read the full United Therapeutics Corporation (UTHR) report, download it here: http://Fundamental-Markets.com/register/?so=UTHR

-----------------------------------------

KCAP FINANCIAL, INC. (KCAP) REPORT OVERVIEW

KCAP Financial's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, KCAP Financial reported revenue of $7.16MM vs $6.25MM (up 14.48%) and analysts estimated basic earnings per share $0.04 vs -$0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, KCAP Financial reported revenue of $28.26MM vs $36.20MM (down 21.92%) and analysts estimated basic earnings per share $0.09 vs -$0.03. Analysts expect earnings to be released on March 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $0.35 and is expected to report on March 6th, 2019.

To read the full KCAP Financial, Inc. (KCAP) report, download it here: http://Fundamental-Markets.com/register/?so=KCAP

-----------------------------------------

GLADSTONE CAPITAL CORPORATION (GLAD) REPORT OVERVIEW

Gladstone Capital's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Gladstone Capital reported revenue of $11.26MM vs $10.83MM (up 3.90%) and analysts estimated basic earnings per share -$0.38 vs $0.21. For the twelve months ended September 30th, 2018 vs September 30th, 2017, Gladstone Capital reported revenue of $45.58MM vs $39.23MM (up 16.18%) and analysts estimated basic earnings per share $0.69 vs $0.67 (up 2.99%). Analysts expect earnings to be released on February 4th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.21. The estimated EPS forecast for the next fiscal year is $0.88 and is expected to report on November 13th, 2019.

To read the full Gladstone Capital Corporation (GLAD) report, download it here: http://Fundamental-Markets.com/register/?so=GLAD

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.